Arda Ural,

Arda Ural is the Americas Life Sciences leader of Ernst & Young (EY), a global professional services firm. For the last five years, he has been leading the life sciences sector of this complex business, comprising strategy, consulting, M&A, technology, tax, and assurance capabilities to surpass $2.0B in revenue with consistent profitable growth. Arda has a proven operational track record in pharma, biotech, med tech, and pharmaceutical services industries with accomplishments in general management, corporate strategy, commercialization, product development, mergers, divestitures, and acquisitions stretching over 30 years, both in the US and globally. Before joining EY, Arda was a Managing Director at Accenture, where he led the firm’s Life Sciences M&A Practice. Earlier, Arda worked as a VP of Strategic Marketing and a BU Leader at Becton Dickinson, a Fortune 500 medical technology company. He also served as the SVP Marketing & Sales for a start-up biotechnology company EyeTech, which went public before getting acquired by Astellas. Arda started his career with Pfizer in Istanbul, Turkey, and subsequently relocated to its New York Headquarters, where he held leadership roles for ten years in commercialization and new product development, such as having launched Viagra worldwide and led the $2B Celebrex business in the US to high growth. He is an inclusive talent leader, has built diverse and high-performing teams that achieved stretched goals. His leadership style is “leading from the front” to make a significant impact on the businesses for which he is accountable. He has a track record of leveraging emerging technologies like Artificial Intelligence to create differentiated growth or cost take-out opportunities. Arda has an engaged network in the industry with leadership roles across several biopharmaceutical associations. Importantly, he was recognized as a PharmaVoice 100 Standout Leader in 2024. Arda was also honored as a “Global Turk par Excellence” by AmCham and Heidrich & Struggles in 2022. He is a start-up mentor to NYU Stern Business School’s incubator program, Endless Frontier Labs. He is the Chair of BioNJ C-Suite Summit and serves as a judge at its BioPartnering Program. He is also a member of the BIO Business Development and Finance Committee and the Emerging Therapeutics Committee. He is an Advisory Board Member of the NJIT Biomedical Engineering Committee, a Member of the In Vivo Editorial Advisory Board. He serves as EY’s executive liaison to Carnegie Hall in New York City and executive sponsor for Liberty Science Center, SciTech Scity Initiative.